Related Experiment Videos
Can denosumab be a substitute, competitor, or complement to bisphosphonates?
Su Young Kim1, Hwoe Gyeong Ok1, Christof Birkenmaier2
1Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University, Yangsan, Korea.
The Korean Journal of Pain
|April 19, 2017
Summary
Denosumab, a biologic agent, offers a new treatment option for osteoporosis by inhibiting osteoclast formation and activity. Its convenient administration and favorable safety profile make it a potential first-line therapy.
Area of Science:
- Bone Biology and Pharmacology
- Osteoporosis Therapeutics
Background:
- Osteoclast differentiation and activity are regulated by receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG).
- RANKL binding to RANK promotes osteoclastogenesis and bone resorption, while OPG binding inhibits it.
- Bisphosphonates (BPs) are current standard treatments for osteoporosis but have limitations.
Purpose of the Study:
- To evaluate denosumab as a potential first-line treatment for osteoporosis.
- To compare the benefits and risks of denosumab against existing therapies.
Main Methods:
- Pharmacological action of denosumab, a monoclonal antibody targeting RANKL.
- Clinical data on denosumab's efficacy, pharmacokinetics, and adverse events.
- Comparison with bisphosphonates regarding administration, gastrointestinal tolerability, and renal function impact.
Main Results:
- Denosumab inhibits osteoclastogenesis by binding to RANKL, reducing bone resorption.
- Treatment with 60 mg denosumab rapidly decreases bone resorption markers.
- Denosumab offers advantages like reversibility, biannual administration, and suitability for impaired renal function.
Conclusions:
- Denosumab's favorable profile supports its consideration as a first-line osteoporosis treatment.
- It is particularly beneficial for patients with poor adherence or contraindications to bisphosphonates.
- Key adverse events include musculoskeletal pain, infections, and hypocalcemia.